LLY

1,010.29

-0.77%↓

JNJ

247.77

-0.21%↓

ABBV

235.04

+0.67%↑

NVS

164.41

-1.49%↓

MRK

120.52

-0.8%↓

LLY

1,010.29

-0.77%↓

JNJ

247.77

-0.21%↓

ABBV

235.04

+0.67%↑

NVS

164.41

-1.49%↓

MRK

120.52

-0.8%↓

LLY

1,010.29

-0.77%↓

JNJ

247.77

-0.21%↓

ABBV

235.04

+0.67%↑

NVS

164.41

-1.49%↓

MRK

120.52

-0.8%↓

LLY

1,010.29

-0.77%↓

JNJ

247.77

-0.21%↓

ABBV

235.04

+0.67%↑

NVS

164.41

-1.49%↓

MRK

120.52

-0.8%↓

LLY

1,010.29

-0.77%↓

JNJ

247.77

-0.21%↓

ABBV

235.04

+0.67%↑

NVS

164.41

-1.49%↓

MRK

120.52

-0.8%↓

Kodu・Aktsiate loetelu・VolitionRX Ltd

VolitionRX Ltd

Avatud

0.19

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.18

Max

0.2

Põhinäitajad
By Trading Economics
Sissetulek	936K -5.4M
Müük	221K 627K
Kasumimarginaal	-857.414
Töötajad	75
EBITDA	1.3M -4.2M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+971.43% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	30. märts 2026

Turustatistika
By TradingEconomics
Turukapital	-21M 26M
Eelmine avamishind	0.19
Eelmine sulgemishind	0.19

VolitionRX Ltd Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. märts 2026, 23:41 UTC

Market Talk

Uudisväärsed sündmused

Nikkei May Decline on Concerns About Energy Prices -- Market Talk

2. märts 2026, 23:37 UTC

Market Talk

Uudisväärsed sündmused

Gold Edges Higher Amid Middle East Conflict -- Market Talk

2. märts 2026, 23:26 UTC

Uudisväärsed sündmused

How the Iran Conflict Could Pressure Consumer Staples Companies -- Barrons.com

2. märts 2026, 22:41 UTC

Market Talk

Australian Reits Wait on Recovery in Trading Multiples -- Market Talk

2. märts 2026, 22:32 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2. märts 2026, 22:32 UTC

Market Talk

RBA Cautious About Potential for Energy Supply Shocks -- Market Talk

2. märts 2026, 22:21 UTC

Market Talk

Port of Tauranga's Upgraded Profit View Still Looks Conservative -- Market Talk

2. märts 2026, 22:11 UTC

Market Talk

Global Equities Roundup: Market Talk

2. märts 2026, 22:11 UTC

Market Talk

Don't Lose Sight of Bigger Picture With Summerset -- Market Talk

2. märts 2026, 22:10 UTC

Omandamised, ülevõtmised, äriostud

IAC Is Near Deal to Sell Care.com to Private-Equity Firm -- WSJ

2. märts 2026, 22:06 UTC

Market Talk

Channel Infrastructure's Dividend Positively Surprises -- Market Talk

2. märts 2026, 22:00 UTC

Market Talk

Tulu

Global Forex and Fixed Income Roundup: Market Talk

2. märts 2026, 22:00 UTC

Market Talk

Tulu

Fashion Retailer Hallenstein Glasson Still a Smart Buy -- Market Talk

2. märts 2026, 21:50 UTC

Market Talk

Uudisväärsed sündmused

Energy & Utilities Roundup: Market Talk

2. märts 2026, 21:50 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

2. märts 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

2. märts 2026, 21:35 UTC

Omandamised, ülevõtmised, äriostud

AT&T Expects Net Debt-To-Adjusted Ebitda Ratio Will Rise to About 3.2x Following Deal With EchoStar and Decline to About 3x by End of 2026

2. märts 2026, 21:34 UTC

Omandamised, ülevõtmised, äriostud

AT&T Remains on Track to Achieve Its 2026 and Multi-Yr Fincl Guidance

2. märts 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

Update: AES to Be Taken Private in $33 Billion Deal. Why It's the S&P 500's Worst Stock Today. -- Barrons.com

2. märts 2026, 21:17 UTC

Uudisväärsed sündmused

Bank, Brokerage Stocks Recover Lost Ground After Last Week's Selloff -- Despite Iran Conflict -- Barrons.com

2. märts 2026, 20:44 UTC

Tulu

Berkshire Stock Falls 5% as Earnings, Abel Letter Fail to Excite Investors -- Barrons.com

2. märts 2026, 20:43 UTC

Market Talk

Uudisväärsed sündmused

Treasury Yields Rise, Dollar Strengthens After Attack on Iran -- Market Talk

2. märts 2026, 20:28 UTC

Tulu

Strategy Stock Rises. The World's Largest Bitcoin Holder Doubles Down on Its Crypto Bet. -- Barrons.com

2. märts 2026, 20:25 UTC

Market Talk

Uudisväärsed sündmused

U.S. Natural Gas Futures Post Moderate Gains -- Market Talk

2. märts 2026, 20:24 UTC

Tulu

Berkshire Stock Falls 5% as Earnings, Abel Letter Fail to Excite Investors -- Barrons.com

2. märts 2026, 20:14 UTC

Omandamised, ülevõtmised, äriostud

Update: AES to Be Taken Private in $33 Billion Deal. Why It's the S&P 500's Worst Stock Today. -- Barrons.com

2. märts 2026, 20:12 UTC

Uudisväärsed sündmused

Palantir Rises on Mideast Conflict. Why It's Moving Like a Defense Stock. -- Barrons.com

2. märts 2026, 20:08 UTC

Market Talk

Uudisväärsed sündmused

Global Forex and Fixed Income Roundup: Market Talk

2. märts 2026, 20:08 UTC

Market Talk

Uudisväärsed sündmused

Higher Oil Prices Could Boost Capex in Canada Energy Patch -- Market Talk

2. märts 2026, 20:05 UTC

Market Talk

Uudisväärsed sündmused

Oil Rises On U.S.-Middle East Conflict, But Settles Off Highs -- Market Talk

Võrdlus sarnastega

Hinnamuutus

VolitionRX Ltd Prognoos

Hinnasiht

By TipRanks

971.43% tõus

12 kuu keskmine prognoos

Keskmine 2.25 USD 971.43%

Kõrge 3 USD

Madal 1.5 USD

Põhineb 3 Wall Streeti analüütiku instrumendi VolitionRX Ltd 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi VolitionRX Ltd aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest VolitionRX Ltd

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.